0
Letters |

Strategies for Preventing HIV Transmission

David R. Holtgrave, PhD
JAMA. 2009;302(14):1530-1532. doi:10.1001/jama.2009.1442
Text Size: A A A
Published online

To the Editor: In their Commentary, Drs Dieffenbach and Fauci1 examined the untested assumptions and implications of the “test and treat” human immunodeficiency virus (HIV) prevention strategy modeled in the study by Granich et al.2 I believe that the Commentary did not address several points relevant to considering this strategy for the United States.

First, the study by Granich et al compared a particular intervention strategy (universal annual testing and immediate HIV treatment) with the absence of that strategy.2 Because many HIV prevention strategies are effective and cost-effective, it is important to identify those intervention options that will most rapidly influence the course of the epidemic. Mathematical models are likely to provide more policy guidance if a variety of intervention strategies are compared with each other.

Second, while the model in Granich et al focused on South Africa, some relevant information about the effect of such a strategy in the United States may be found in other studies. The Centers for Disease Control and Prevention has estimated that approximately 30% to 46% of the US cases of sexual transmission of HIV are from persons aware of their HIV seropositivity (assuming a 60% level of treatment and that 54.5% of persons in treatment have a viral load of less than 500 copies/mL).3 In the United States, perfect awareness of HIV seropositivity would be estimated to decrease HIV incidence by no more than approximately 40%.4

Third, a recent estimate of the US annual HIV transmission rate5 found that since 1991 the only increase in the transmission rate was in 1997, just after the advent of highly active antiretroviral therapy (ART). This suggests that the national effect of treatment availability is likely a complex function of biological, clinical, behavioral, and social factors.

Given these challenges, the Granich et al model may not be the optimal framework to guide the National Institutes of Health HIV prevention agenda.

AUTHOR INFORMATION

Financial Disclosures: None reported.

REFERENCES

Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission.  JAMA. 2009;301(22):2380-2382
PubMedCrossRef
Granich RM, Gilks CF, Dye C, DeCock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.  Lancet. 2009;373(9657):48-57
PubMedCrossRef
Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA.  AIDS. 2006;20(10):1447-1450
PubMedCrossRef
Holtgrave DR, Pinkerton SD. Can increasing awareness of HIV seropositivity reduce infections by 50% in the United States?  J Acquir Immune Defic Syndr. 2007;44(3):360-363
PubMedCrossRef
Holtgrave DR, Hall IH, Rhodes PH, Wolitski RJ. Updated annual HIV transmission rates in the United States, 1977-2006.  J Acquir Immune Defic Syndr. 2009;50(2):236-238
PubMedCrossRef

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission.  JAMA. 2009;301(22):2380-2382
PubMedCrossRef
Granich RM, Gilks CF, Dye C, DeCock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.  Lancet. 2009;373(9657):48-57
PubMedCrossRef
Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA.  AIDS. 2006;20(10):1447-1450
PubMedCrossRef
Holtgrave DR, Pinkerton SD. Can increasing awareness of HIV seropositivity reduce infections by 50% in the United States?  J Acquir Immune Defic Syndr. 2007;44(3):360-363
PubMedCrossRef
Holtgrave DR, Hall IH, Rhodes PH, Wolitski RJ. Updated annual HIV transmission rates in the United States, 1977-2006.  J Acquir Immune Defic Syndr. 2009;50(2):236-238
PubMedCrossRef
October 14, 2009
Seth Kalichman, PhD; Lisa Eaton, MA
JAMA. 2009;302(14):1530-1532.
October 14, 2009
Carl W. Dieffenbach, PhD; Anthony S. Fauci, MD
JAMA. 2009;302(14):1530-1532.
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.